Berlin / Frankfurt - The annual general meeting of MagForce Nanotechnologies AG has elected a new supervisory board. The new supervisory board consisting of three members will fulfill its statutory responsibilities for overseeing the company over the next five years. The new members are Dr. Walter Rust, an attorney and notary in Berlin; Dr. Peter Heinrich, co-founder and chairman of the management board of MediGene AG; and Professor Wolfgang M. Heckl, a noted scientist in nanotechnology research and general director of the Deutsches Museum, the world-famous museum of science and technology in Munich.

Following the AGM, Dr. Walter Rust was elected to serve as chairman of the supervisory board. As an attorney and notary in Berlin, as well as an accredited attorney-at-law in the State of New York, Dr. Rust advises technology companies throughout Germany on issues of company law, venture capital financing, licensing agreements and international contract law. He also serves as a lecturer and member of the MBA Advisory Board for the Berlin School of Economics as well as a lecturer at the Technical University of Berlin.

Dr. Peter Heinrich was elected as the deputy chairman of the supervisory board. Dr. Heinrich is the co-founder of MediGene AG and has served as the CEO since 1995. Prior to this he was at Wacker Chemie AG for almost eight years, where his responsibilities included building the biotechnology business as well as the management of international alliances. Dr. Heinrich is speaker and chairman of the executive board of BIO-Deutschland, an independent organization representing the interests of the German biotechnology industry. He also serves on the advisory board of the German Chemical Industry Association (VCI) and on the board of trustees of Bayern Innovativ GmbH. Beyond this, he is on the advisory board of Wirtschaftsrat Deutschland (German Economic Council) as part of the national expert group for growth and innovation, is a mentor and tutor at the Bavarian Elite Academy, and is on the supervisory board of the University of Augsburg’s MBA program.

Professor Wolfgang M. Heckl was elected as the third member of the supervisory board. Professor Heckl is considered one of the world’s leading experts in the field of nanotechnology. His commitment to ongoing research in nanotechnology from its very early stages and to building public awareness of this groundbreaking technology were recognized in 2004, when he received the European Union’s Descartes Prize for Science Communication. Heckl has been professor of experimental physics at the Ludwig Maximilian University (LMU) in Munich since 1993, and general director of Germany’s largest science museum, Munich’s renowned Deutsches Museum, since 2004. He is involved in various scientific associations, including the Excellence Network NanoBioTechnology, as well as centers of scientific excellence such as the Center for NanoScience and the GeoBioCenter at the LMU in Munich.

"We are extremely pleased to have three such distinguished members bring their vision to our supervisory board, along with their expertise and worldwide reputations in the areas of law, business and science," declared Dr. Uwe Maschek, CEO of MagForce Nanotechnologies AG. "The new supervisory board will stand ready to advise the company regarding all important issues and to provide intensive support for the future market introduction of its nanotechnology-based cancer therapy."

"Following the successful expansion of the management board in May of this year and the appointment now of the new supervisory board, we see the company as well equipped for the upcoming regulatory approval and commercialization phase. As an investor, we welcome this development very much and look forward to continued positive news from the company," added Marco Beckmann, CEO of Nanostart AG.

About Nanostart:
Nanostart AG is Europe’s leading nanotechnology investment company, with headquarters in Frankfurt, Germany. The company is organized into two divisions: the Portfolio Division, which manages its own investment holdings; and the Financial Services Division, which advises financial service providers on investing in the nanotechnology sector.

About MagForce Nanotechnologies:
MagForce Nanotechnologies AG is the world’s leading company in the area of nanotechnology-based cancer treatment. Its patented therapy allows the targeted destruction of tumors using magnetic nanoparticles. MagForce’s nanotechnology represents a revolutionary approach to the future successful treatment of solid tumors.

DISCLAIMER:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.

Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax:     +49 (0)69-21 93 96 122
e-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it